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I S221 I Gene Therapy for Cystic Fibrosis: Where Do We 
E.W.EW Alton. Ion Transport Unit, National Heart G Lung Institute, 
London, United Kingdom 
The cystic fibrosis (CF) gene was cloned was in 1989, and the feasi- 
bility of in vitro gene theram demonstrated by 1991. With the devel- 
opment of CF mouse models, two groups demonstrated that CFTR 
gene transfer is able to correct, at least in part, the bioelectrical ab- 
normality characteristic of CE As a result of these and other studies, 
CF gene therapy has moved into the clinical arena. Currently, 4 &- 
ical trials have been reported with at least another dozen underway 
or recently completed. The preliminary data available from these 
studies suggests that both adenowal and cationic liposome medlated 
gene transfer can be demonstrated at the level of both mRNA and 
protein. With respect to functional correction, approximately 30% 
of subjects studied have demonstrated evidence of some degree of 
correction of the chloride abnormality characteristic of CE A num- 
ber of safety issues have arisen with regard to adenoviral mediated 
gene transfer, whilst to date liposomes have proved to be safe. The 
data from these studies will be reviewed in this presentation. 
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I S224 I Latest Lessons from Experimental Models 
M.G. Bergeron. Lavaf University, Quibec city, Canada 
Objectives: Anunal models have been traditionally used to evaluate 
the pathogenesis of infectious diseases or to investigate the safety, 
pharmacokmetics, pharmacodynamics and/or efficacy of antimicro- 
bials. From these models, parameters of antibiotic use have evolved 
and have helped in the management of specific diseases like menin- 
gitis or endocarditis. Recently some antibiotics have been shown 
to modulate host response. Appropriately designed, experimental 
models may become powerful tools to explore not only the in vivo 
antimicrobial activity of antibiotics but their Biological Response 
Modifiers (BRM) properties. 
Methods: A murine model of pneumococcal pneumonia was 
developed i) to study the chronology of events which mediates the 
progression of the inflammatory response and leads to death, ii) to 
detect specific markers of disease progression, and iii) to evaluate 
how antibiotics can interact with the immune system and control 
this deadly infection. 
Results: There was no correlation between the kinetics of cy- 
tokines in blood and that observed in bronchoalveolar fluid PAL) 
or lung. The simultaneous elevation of IL-6 and TNF observed in 
blood may be a sign of poor prognosis and imminent death, whde 
high level of IL-6 may suggest early disease mth  limited lung dam- 
age. In this model, cefodizime (Cet) dld reduce the level of LTB4 
and neutrophil recruitments in the lungs of infected animals. More- 
over, this B-lactam dld selectively inhibit TNF and IL-6 in BAL and 
lung tissue without altering IL-1 production. By reducing the over- 
w h e h n g  dammatory response that occurs during severe pneu- 
monia, thrs antibiotic may protect the host in unique ways. 
Conclusions: Animal studies based at developing strateges of 
immune modulation may eventually lead to therapies of unparalleled 
efficacy and safety. 
182251 Understanding Host Defence Mechanisms by 
J.Y. Cesbron. F 
No abstract available. 
Gene Manipulation 
I S226 I Pneumonia: News from the Experimental 
Models 
WR. Wdson. USA 
No abstract available. 
Evolving natural history and prognostic 
factors in febrile neutropenia 
(ESCMID Working Party on Infections in 
Cancer Patients) 
[El Evolving Natural History and Prognostic Factors 
M. Paesmans, K. Rolston, E. Rubenstein, R. Feld, B. De Pauw, 
M.F! Glauser, A. Cometta, J. Klasteaky for the h4ASCC Infectious 
Committee. InstitutJufes Bordet, BmseL, Belgium 
Since December 1994, the Infectious Committee of the Multi- 
national Association for Supportive Care in Cancer (MASCC) is 
conducting a survey, in a multicenhic, multinational setting among 
febrile neumpenic cancer patients @ts) in order to idennfy features 
at presentation able to predict a good outcome or the occurrence of 
a serious medlcal complication with a particular interest in an ex- 
ternal validation of the prediction rule published by Talcott in JCO 
(1992) where pts are allocated into 4 groups: I: inpts, 11: outpts with 
comorbidity, 111: outpn with unconmlled cancer, M outpts with- 
out comorbidity or uncontrolled cancer. Up to January 31, 1997, 
about 900 eligible pts have been followed for one episode. Interim 
descriptive results currently available are the following: median age is 
52 yn with 49% of male pts. Underlying &ease was hematologic in 
46%, lymphoma/Hodgkinb disease in 20%. solid tumor in 26% and 
other in 9 %  23% did undergo a transplantation. A clinical site was 
found in 42% and TalcottS group distribution was: I:62%, II:13%, 
III:9% and IV16%. Initial empiric antibiotic treatment was success- 
ful in 55%, a serious medical complication occurred in 17% with 
a 7% death rate. Closure of the survey d occur soon, after 1000 
episodes and defimtive results including inferential analysis will be 
available at the meeting. 
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I S228 I Evolving natural history and prognostic factors 
in Febrile Neutropenia 
C. Verhagen. Uniwnity Hospital Nqmegen (AZN), The Netherlands 
Objectives: To determine the incidence of infection, febrile neu- 
tropenia and related factors after chemotherapy for solid tumors. 
Methods: Retrospective study of all patients treated for solid tu- 
mors during 8 years (1982-1989) followed by prospective studies of 
febrile neutropenia tiom 1990-1996 in a slngle institution (AZN). 
Results: From 1982-’89,638 patients underwent 2767 courses of 
chemotherapy which resulted in 197 (7%) episodes of neutropenia. 
The incidence of febrile neutmpenia was 67/197 (34%); 41% micro- 
biologically proven mfections (1 1% gram positive, 8% gram negative, 
10% polymicrobial and 12% fungal), 37% c h d y  localized infec- 
tions and 22% episodes without any detectable focus (FUO). The 
mortality was 5/67 (7.5%). From 1990-1996,60 neutmpenic febrile 
patients participated in three prospective stumes; 43% microbiologi- 
cally proven mfections (10% gram positive. 20% gram negative, 10% 
polymicrobial and 3% other infections), 10% clinically localized in- 
fections and 47% FUO. The mortality was 2/60 (3%). 
Conclusions: The incidence of infections or neutropenic febrile 
episodes is low after chemotherapy for all solid tumors. In case neu- 
tmpenia occurs the incidence of neutmpenic febrile episodes is high 
(37%) with a mortality of 3-7.5%. The majority of mfections re- 
mains gram-negative microorganisms. 
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